[Chinese expert consensus on the diagnosis and management of Epstein-Barr virus positive diffuse large B cell lymphoma (2025)].

Epstein-Barr virus positive diffuse large B cell lymphoma (EBV(+) DLBCL) is a rare subtype of diffuse large B cell lymphoma with a poor prognosis. Due to the low incidence of EBV(+) DLBCL, the understanding of the disease has not been unified, and the treatment remains non-standardized. In order to strengthen the understanding of EBV(+) DLBCL in our country, improve the diagnosis and treatment level, and help promote multi-center clinical research, the Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association and Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO) organized relevant experts to discuss and form this consensus on the diagnosis and treatment of EBV(+) DLBCL, combined with the latest research progress in China and abroad.